5 Things to Know Before the Stock Market Opens

U.S. stock futures are slightly lower as investors brace for a heavy earnings week and watch Iran developments. Dominion Energy is surging after announcing an acquisition by NextEra Energy, while UnitedHealth is weaker after Berkshire Hathaway disclosed it sold its stake in the insurer. Regeneron is tumbling on disappointing clinical trial results, adding to single-stock volatility.

Analysis

The market is being pulled in three different directions: event risk into a dense mega-cap earnings week, idiosyncratic de-risking in healthcare, and a classic M&A arb setup in utilities. The earnings names are not catalysts in isolation; the real setup is dispersion. Into a week like this, implied correlation tends to fall while index-level volatility can stay sticky, which favors relative value over outright beta. That argues for avoiding naked exposure to the headline-heavy consumer/electro names until results clear and positioning resets.

UNH looks more vulnerable than the tape suggests because a prominent holder exit can change the marginal buyer base even if the fundamental thesis is intact. The first-order move is about sentiment, but the second-order effect is index and factor pressure: a lower multiple can bleed into managed-care peers if investors reprice regulatory and reimbursement risk together. In contrast, REGN’s drawdown is the kind that often creates a multi-week overreaction window, but only if the trial miss does not alter the platform value case; if it does, the selloff can persist for months as pipeline optionality gets discounted harder.

The D/NEE situation is where the cleaner trade lives. Once deal spread compression begins, the target becomes a low-vol carry asset and the acquirer inherits integration and financing scrutiny, so the spread should be judged against break risk rather than headline premium. Geopolitics adds a tail-risk overlay: any escalation in Iran likely supports energy and broadens market dispersion, but it also raises the probability of a risk-off flush that can temporarily overwhelm single-name M&A and biotech moves. The key is timing: earnings-driven volatility should fade over days if beats/misses are clean, while healthcare reratings and deal spreads can persist for weeks.